Arthur Sillah1, Nathaniel F Watson2, Ulrike Peters3, Mary L Biggs4, F Javier Nieto5, Christopher I Li3, David Gozal6, Timothy Thornton4, Sonnah Barrie7, Amanda I Phipps3. 1. University of Washington School of Public Health, United States; Fred Hutchinson Research Cancer Research Center, United States. Electronic address: asillah@uw.edu. 2. Department of Neurology, University of Washington School of Medicine, United States. 3. University of Washington School of Public Health, United States; Fred Hutchinson Research Cancer Research Center, United States. 4. University of Washington School of Public Health, United States. 5. Oregon State University College of Public Health and Human Sciences, Corvallis, OR, United States. 6. Department of Child Health, University of Missouri School of Medicine, United States. 7. Burrell College of Osteopathic Medicine, University Park, NM, United States.
Abstract
BACKGROUND: Sleep problems (SP) can indicate underlying sleep disorders, such as obstructive sleep apnea, which may adversely impact cancer risk and mortality. METHODS: We assessed the association of baseline and longitudinal sleep apnea and insomnia symptoms with incident cancer (N = 3930) and cancer mortality (N = 4580) in the Cardiovascular Health Study. We used Cox proportional hazards regression to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CI) to evaluate the associations. RESULTS: Overall, 885 incident cancers and 804 cancer deaths were identified over a median follow-up of 12 and 14 years, respectively. Compared to participants who reported no sleep apnea symptoms, the risk of incident cancer was inversely associated [(HR (95%CI)] with snoring [0.84 (0.71, 0.99)]. We noted an elevated prostate cancer incidence for apnea [2.34 (1.32, 4.15)] and snoring [1.69 (1.11, 2.57)]. We also noted an elevated HR for lymphatic or hematopoietic cancers [daytime sleepiness: 1.81 (1.06, 3.08)]. We found an inverse relationship for cancer mortality with respect to snoring [0.73 (0.62, 0.8)] and apnea [(0.69 (0.51, 0.94))]. We noted a significant inverse relationship between difficulty falling asleep and colorectal cancer death [0.32 (0.15, 0.69)] and snoring with lung cancer death [0.56 (0.35, 0.89)]. CONCLUSIONS: The relationship between SP and cancer risk and mortality was heterogeneous. Larger prospective studies addressing more cancer sites, molecular type-specific associations, and better longitudinal SP assessments are needed for improved delineation of SP-cancer risk dyad.
BACKGROUND: Sleep problems (SP) can indicate underlying sleep disorders, such as obstructive sleep apnea, which may adversely impact cancer risk and mortality. METHODS: We assessed the association of baseline and longitudinal sleep apnea and insomnia symptoms with incident cancer (N = 3930) and cancer mortality (N = 4580) in the Cardiovascular Health Study. We used Cox proportional hazards regression to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CI) to evaluate the associations. RESULTS: Overall, 885 incident cancers and 804 cancer deaths were identified over a median follow-up of 12 and 14 years, respectively. Compared to participants who reported no sleep apnea symptoms, the risk of incident cancer was inversely associated [(HR (95%CI)] with snoring [0.84 (0.71, 0.99)]. We noted an elevated prostate cancer incidence for apnea [2.34 (1.32, 4.15)] and snoring [1.69 (1.11, 2.57)]. We also noted an elevated HR for lymphatic or hematopoietic cancers [daytime sleepiness: 1.81 (1.06, 3.08)]. We found an inverse relationship for cancer mortality with respect to snoring [0.73 (0.62, 0.8)] and apnea [(0.69 (0.51, 0.94))]. We noted a significant inverse relationship between difficulty falling asleep and colorectal cancer death [0.32 (0.15, 0.69)] and snoring with lung cancer death [0.56 (0.35, 0.89)]. CONCLUSIONS: The relationship between SP and cancer risk and mortality was heterogeneous. Larger prospective studies addressing more cancer sites, molecular type-specific associations, and better longitudinal SP assessments are needed for improved delineation of SP-cancer risk dyad.
Authors: F Javier Nieto; Paul E Peppard; Terry Young; Laurel Finn; Khin Mae Hla; Ramon Farré Journal: Am J Respir Crit Care Med Date: 2012-05-20 Impact factor: 21.405
Authors: Marcin Paciorek; Piotr Korczyński; Piotr Bielicki; Krzysztof Byśkiniewicz; Jan Zieliński; Ryszarda Chazan Journal: Sleep Med Date: 2011-03 Impact factor: 3.492
Authors: S F Quan; B V Howard; C Iber; J P Kiley; F J Nieto; G T O'Connor; D M Rapoport; S Redline; J Robbins; J M Samet; P W Wahl Journal: Sleep Date: 1997-12 Impact factor: 5.849
Authors: B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: David Gozal; Isaac Almendros; Amanda I Phipps; Francisco Campos-Rodriguez; Miguel A Martínez-García; Ramon Farré Journal: Int J Mol Sci Date: 2020-11-20 Impact factor: 5.923